EPO, erythropoietin, 2056

N. diseases: 646; N. variants: 11
Disease: Fatigue ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015672
Disease: Fatigue
Fatigue 		0.330 Biomarker phenotype BEFREE Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. 29719440 2018
CUI: C0015672
Disease: Fatigue
Fatigue 		0.330 Biomarker phenotype BEFREE Combined treatment with EPO and EA was well tolerated, and all 18 patients who suffered from fatigue prior to therapy recovered. 27271482 2017
CUI: C0015672
Disease: Fatigue
Fatigue 		0.330 Therapeutic phenotype CTD_human A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. 18695134 2008
CUI: C0015672
Disease: Fatigue
Fatigue 		0.330 Biomarker phenotype BEFREE Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. 15856028 2005